Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
2.980
-0.060 (-1.97%)
Aug 24, 2026, 4:00 PM EDT - Market closed

Elicio Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-37.92-37.71-44.99-35.75-23.73-25.47
Net Income
-37.84-39.57-51.9-35.2-28.21-26.4
Earnings Per Share
-2.17-2.58-4.25-6.96-89.27-1.73
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
23.4818.5617.6212.896.169.28
Total Debt
14.1514.5126.046.927.4811.8
Net Cash (Debt)
9.334.05-8.425.98-1.33-2.52
Net Cash Growth
29.86%-----
Net Cash Per Share
0.540.26-0.691.18-4.19-0.16

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-37.69-36.95-37.07-32.69-22.18-23.94
Capital Expenditures
-0.02-0.02-0.09-0.07-0.65-0.53
Free Cash Flow
-37.71-36.97-37.16-32.76-22.83-24.46
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.